Dr.Guttler’s comments:

1. 29 patients with 49 recurrent episodes were followed from 60-114 months.

2. Volume reduction was 99.5%

3. 42/47 (91.3%) had complete ablation.

4. No delayed complication found.

5. RFA seems to be an effective minimally invasive therapy for the treatment of locally recurrent PTC even in the longer-term period.

6. RFA is an effective local control treatment option for recurrent PTCs even in the longer-term period with mean tumor VRR of 99.5% and the complete disappearance of the treated tumors in 91.3%.

7. Call me at 310-393-8860 or email to thyroid.manager@thyroid.com for details how I can save you from the need for more surgery.

8. Ask for Alicia.

9. Dr.G.

Longer-term outcomes of radiofrequency ablation for locally recurrent papillary thyroid cancer

• Sae Rom Chung, 
• Jung Hwan Baek, 
• Young Jun Choi & 
• Jeong Hyun Lee 

European Radiology volume 29, pages4897–4903 (2019)Cite this article

• 599 Accesses
• 27 Citations
• Metricsdetails

Abstract

Objectives

The purpose of this study was to evaluate the longer-term efficacy of ultrasound (US)-guided radiofrequency ablation (RFA) for treating locally recurrent papillary thyroid cancer (PTC).

Methods

We retrospectively reviewed 29 patients who underwent RFA for 46 recurrent PTC between September 2008 and April 2012 and were subsequently followed up for at least 5 years. Follow-up included size change on US and thyroglobulin (Tg) level at 1, 3, 6, and 12 months and every 6–12 months thereafter. Any complications were reported during follow-up.

Results

The mean follow-up duration after RFA was 80 ± 17.3 months (range, 60–114 months). Tumor volume decreased significantly, from 0.25 ± 0.42 mL before ablation to 0.01 ± 0.08 mL at the final evaluation (p < 0.001), with a mean volume reduction of 99.5% ± 2.9%. Forty-two of the 46 treated tumors (91.3%) had completely disappeared by the final evaluation. The mean serum Tg level decreased from 2.55 ± 4.7 to 0.75 ± 1.83 ng/dL (p < 0.001). There were no delayed complications associated with RFA during the follow-up period.

Conclusions

RFA seems to be an effective minimally invasive therapy for the treatment of locally recurrent PTC even in the longer-term period.

Key Points

• RFA is an effective local control treatment option for recurrent PTCs even in the longer-term period with mean tumor VRR of 99.5% and the complete disappearance of the treated tumors in 91.3%.

• The mean serum Tg level decreased significantly after RFA and biochemical remission rate was 51.7%.

• No delayed complication after RFA for local recurrent PTC.